Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Not Applicable

Completed

• Conditions: Diabetic Nephropathy

• Registration Number: NCT00240019
• Lead Sponsor: Stanford University

Brief Summary

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-12
• Study First Submitted: 2005-10-13
• Study First Submitted QC: 2005-10-13
• Study First Posted: 2005-10-17
• Study Completion: 2006-04
• Status Verified: 2006-06
• Last Update Submitted: 2006-10-16
• Last Update Posted: 2006-10-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

proteinuria greater than 1 gram/day serum creatinine < 2.6 for men, < 2.0 for women

Exclusion Criteria

blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
The amount of protein in the urine after 8 weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
The estimated glomerular filtration rate after 8 weeks of treatment.

Trial Locations

Locations (2)

Stanford University Medical Center; 🇺🇸 Stanford, California, United States

Kaiser Permanente of Northern California, Santa Clara and San Jose; 🇺🇸 Santa Clara, California, United States